Periprosthetic Fracture Registry (PPFx)
Launched by AO INNOVATION TRANSLATION CENTER · Dec 19, 2017
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The Periprosthetic Fracture Registry (PPFx) is a clinical study that collects information about patients who have experienced fractures around their hip or knee joint replacements. The goal of this registry is to gather data that can help improve treatments for these fractures, enhance patient safety, and ultimately improve the overall quality of care for those who undergo hip or knee surgeries. By understanding the best ways to treat these injuries, the registry aims to reduce complications and healthcare costs while advancing orthopedic science.
To participate in the study, individuals must be at least 18 years old and have had a fracture after receiving total or partial hip or knee joint replacements. They should be able to understand the study information and provide consent to participate, as well as attend follow-up appointments after their surgery. However, pregnant women or those planning to become pregnant during the study, as well as prisoners, cannot take part. If eligible, participants can expect to contribute valuable information that may help improve treatment for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Post-operative PPFx after total or hemi hip or total or unicondylar knee arthroplasty (including the acetabulum, femur, patella and proximal tibia) requiring
- • osteosynthesis alone or
- • component revision plus plate/nail osteosynthesis
- * Informed consent obtained, i.e.:
- • Ability of the patient or assigned representative to understand the content of the patient information / Informed Consent Form
- • Signed and dated EC / IRB approved written informed consent
- • Ability to attend post-operative follow up visits
- Exclusion Criteria:
- • Pregnancy or women planning to conceive within the study period
- • Prisoner
About Ao Innovation Translation Center
The AO Innovation Translation Center (AO ITC) is a leading clinical trial sponsor dedicated to advancing orthopedic research and innovation. With a focus on translating cutting-edge scientific discoveries into clinical applications, AO ITC collaborates with healthcare professionals, researchers, and industry partners to facilitate the development of novel therapies and technologies. By leveraging its extensive network and expertise, AO ITC aims to enhance patient care and outcomes in the field of musculoskeletal health, ensuring that innovative solutions are efficiently brought to market and accessible to those in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Basel, , Switzerland
Zürich, , Switzerland
Münster, , Germany
Berlin, , Germany
Bogotá, , Colombia
Columbia, Missouri, United States
Nashville, Tennessee, United States
Palma De Mallorca, , Spain
Jersey City, New Jersey, United States
Livingston, New Jersey, United States
Leuven, , Belgium
Ludwigshafen, , Germany
Liestal, , Switzerland
Patients applied
Trial Officials
Karl Stoffel, MD
Principal Investigator
Universitätsspital Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials